EU Eyes Joint Purchase of Covid Treatments in Long Virus Fight
(Bloomberg) -- The European Commission will propose the joint procurement of Covid-19 treatments, as it seeks to secure supplies of potentially critical drugs for the period past the acute phase of the pandemic, according to a document seen by Bloomberg.
The plan by the European Union's executive arm sets out the need for a common European framework for the development and deployment of targeted therapeutics for coronavirus patients and aims to avoid a patchwork of policies across the 27-nation bloc. The commission is due to adopt the proposal on Wednesday and unveil it on Thursday.
Pfizer Inc., Merck & Co., Novartis AG and Roche Holding AG are among the companies investing in potential treatments for Covid, from antiviral pills to shots. They are betting that vaccines alone won't be enough to halt the spread of the disease, meaning that people might not only need regular shots for years to come but also medicines to help those who've gotten sick.
Securing the supply of such treatments will limit the need for hospitalization, speed up recovery times and ultimately save lives of citizens across the bloc, the commission says in the draft of the plan seen by Bloomberg. Its aim is to have three new therapeutics available by October 2021 and possibly two more by year-end. At the moment, Remdesivir is the only Covid-19 treatment authorized at EU level.
The push aims to complement the EU's strategy for Covid-19 vaccines in the medium term and highlights how the bloc expects the management of Covid to be a key priority in the medium term even after a significant segment of its population is fully vaccinated. As inoculations are picking up pace across the bloc, the commission is also looking to finalize a contract with Pfizer and BioNTech SE to deliver a massive supply of their vaccines to the bloc.
The vaccine deal is expected to cover 1.8 billion additional Covid doses through 2023, with production largely taking place within the EU. The doses would mainly include booster shots and doses for children, officials have said.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.